BMAL1–HIF2α heterodimer was recently shown to modulate circadian variations in myocardial injury. Here, the authors show that BMAL1 can form a heterodimer with HIF2α in clear cell renal cell carcinoma, contributing to tumor progression and response to HIF2α antagonist drugs.
- Rebecca M. Mello
- Diego Gomez Ceballos
- Katja A. Lamia
